Skip to content
AnalystLens

Omega Healthcare Investors 8-K Report, Corporate Update (Mar 12, 2024)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed March 12, 2024
Period End
March 12, 2024
Security
OHI
In the record · 2016–202610-K1210-Q348-K126

OHI filed 12 annual reports (10-K), 34 quarterly reports (10-Q) and 126 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · May ’17May ’17
  2. Material agreement8-K · Oct ’20Oct ’20
  3. Leadership change8-K · Jan ’23Jan ’23
  4. Leadership change8-K · Oct ’26Oct ’26

Summary

Summary of the 8-K filed March 12, 2024. Cited figures are marked; the original filing is the authoritative source.

Omega Healthcare Investors, Inc. filed this Form 8-K on March 12, 2024 to report that the Circuit Court for Baltimore City granted preliminary approval, on February 28, 2024, to a proposed settlement of certain shareholder derivative actions.

The settlement, set out in a Stipulation of Settlement dated February 22, 2024, involves plaintiffs Stourbridge Investments LLC, Phillip Swan, Tom Bradley, and Sarah Smith, with the Company as nominal defendant. The actions cover the Maryland State Action (Swan v. Pickett and Bradley v.

Callen) and the New York Federal Action (Stourbridge Investments LLC v. Callen). The Court has scheduled a final approval hearing for May 21, 2024, at 2:00 p.m.

Eastern Time. The settlement's operative consideration is non-monetary. Under Exhibit A to the Stipulation, the Company agrees to adopt corporate governance reforms within 60 days after the Effective Date, and these reforms remain in effect for a three-year Effective Term.

The reforms cover areas including credit risk oversight by the Chief Operating Officer, a Disclosure Committee, audit committee enhancements, insider trading policy changes, and clawback policy updates. The Notice states there is no claims procedure and no payment to individual shareholders. The Company, or its insurers, agreed to pay plaintiffs' counsel attorneys' fees and expenses of $1,950,000,a subject to court approval.

The defendants deny all wrongdoing, and the Stipulation states that it is not an admission of liability. For investors, the filing is primarily a governance and procedural disclosure.

It sets out the terms of the derivative settlement, the approval timetable, and the governance commitments the Company will adopt. The filing does not state any financial impact on the Company beyond the fee amount.

Key Highlights

  1. Circuit Court for Baltimore City granted preliminary approval on February 28, 2024 to a proposed settlement of shareholder derivative actions, based on a Stipulation of Settlement dated February 22, 2024.
  2. Final approval hearing is scheduled for May 21, 2024, at 2:00 p.m. Eastern Time, before Judge Lawrence P. Fletcher-Hill.
  3. Settlement consideration is non-monetary: the Company will adopt and maintain corporate governance reforms for a three-year Effective Term.
  4. Governance reforms span 17 categories, including credit risk oversight by the Chief Operating Officer, a Disclosure Committee, audit committee enhancements, and insider trading policy changes.
  5. Plaintiffs' counsel fees and expenses of $1,950,000 are payable by the Company or its insurers, subject to court approval.
  6. No claims procedure applies, as the settlement results in governance changes rather than payments to shareholders.
  7. Defendants deny all wrongdoing, and the Stipulation states it is not an admission of liability.

Frequently Asked Questions

  1. What is the settlement about?

    The settlement resolves shareholder derivative lawsuits brought on behalf of Omega. The claims relate to a $15.2 million Working Capital Loan extended in 2017 to operator Orianna Health Systems, and allege breaches of fiduciary duty and misleading disclosures. The defendants deny the allegations.

  2. Will shareholders receive a payment from this settlement?

    No. The filing states that the Settlement will result in changes to the Company's corporate governance, not payment to individuals, and that there will be no claims procedure.

  3. What does the Company have to pay?

    The Company, or its insurers, agreed to pay or cause to be paid $1,950,000 in attorneys' fees and expenses to plaintiffs' counsel, subject to court approval. Plaintiffs may also apply for service awards of $3,000 to each plaintiff, funded from that amount.

  4. When will the court decide on final approval?

    The court scheduled the Settlement Hearing for May 21, 2024, at 2:00 p.m. Eastern Time. Written objections from shareholders were due by May 7, 2024, according to the Summary Notice in Exhibit 99.2.

  5. How long do the governance reforms last?

    The Corporate Governance Reforms remain in effect for not less than the Effective Term, which is three years from the Effective Date. The Board may modify them if required by applicable law or its fiduciary duties under Maryland law.